Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study (Q34488726)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

object named as

Susan L Cohn

14

0 references

7

object named as

C Patrick Reynolds

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert C Seeger

6

object named as

Robert C Seeger

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

object named as

Wendy B London

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

18

object named as

John M Maris

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Suzanne Shusterman

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Stephen D Gillies

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jacquelyn A Hank

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Stephan D Voss

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jennifer Kimball

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mark R Albertini

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Barrett Wagner

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jacek Gan

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jens Eickhoff

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Kenneth B DeSantes

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Toby Hecht

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Brian Gadbaw

16

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ralph A Reisfeld

17

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Paul M Sondel

19

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

4 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

4969-4975

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

6 July 2018

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

27 October 2018

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

27 October 2018

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

27 October 2018

A mechanism for neutrophil-mediated lysis of human neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

27 October 2018

FCGR2APolymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020698

9 December 2018

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20921469

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.27.8861

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34488726&oldid=2186462511"